Shares of Burning Rock Biotech Limited (NASDAQ:BNR - Get Free Report) shot up 0.1% during mid-day trading on Tuesday . The company traded as high as $7.39 and last traded at $7.06. 8,916 shares changed hands during trading, an increase of 79% from the average session volume of 4,979 shares. The stock had previously closed at $7.05.
Burning Rock Biotech Stock Performance
The company has a market capitalization of $72.32 million, a P/E ratio of -2.35 and a beta of 0.55. The stock has a fifty day moving average of $5.55 and a 200 day moving average of $5.27.
Institutional Investors Weigh In On Burning Rock Biotech
An institutional investor recently bought a new position in Burning Rock Biotech stock. SkyView Investment Advisors LLC bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the company's stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned approximately 0.10% of Burning Rock Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 30.03% of the company's stock.
Burning Rock Biotech Company Profile
(
Get Free Report)
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Featured Stories
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
